PT - JOURNAL ARTICLE AU - Ashraf, Sohaib AU - Ashraf, Shoaib AU - Imran, Muhammad Ahmad AU - Ashraf, Moneeb AU - Kalsoom, Larab AU - Siddiqui, Uzma Nasim AU - Ghufran, Muhammad AU - Majeed, Nighat AU - Farooq, Iqra AU - Habib, Zaighum AU - Hilal, Abubakar AU - Zain-ul-Abdin AU - Khaqan, Ayesha AU - Akram, Muhammad Kiwan AU - Ashraf, Sidra AU - Akmal, Rutaba AU - Rafique, Sundas AU - Nawaz, Khawar AU - Arshad, Shahroze AU - Ahmad, Sohail AU - Hayat, Kanwal AU - Arshad, Ali AU - Nadeem, Muhammad Faisal AU - Hassan, Muhammad AU - Abeer-bin-Awais AU - Azam, Muhammad AU - Suhail, Muhammad AU - Zulfiqar, Sibgha AU - Anwar, Imran AU - Sarfraz, Saulat AU - Hamayoun, Ayesha AU - Malik, Amber AU - Zheng, Hui AU - Mahmood, Talha AU - Ayyaz, Mahmood AU - Ahmad, Ali AU - Ashraf, Muhammad AU - Saboor, Qazi Abdul AU - Izhar, Mateen TI - Efficacy of honey and <em>Nigella sativa</em> against COVID-19: HNS-COVID-PK Trial AID - 10.1101/2020.10.30.20217364 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.30.20217364 4099 - http://medrxiv.org/content/early/2020/11/06/2020.10.30.20217364.short 4100 - http://medrxiv.org/content/early/2020/11/06/2020.10.30.20217364.full AB - BACKGROUND No definitive treatment exists for Coronavirus Disease 2019 (COVID-19). Honey and Nigella sativa (HNS) has established anti-viral properties. Hence, we investigated efficacy of HNS against COVID-19.METHODS We conducted a multicenter-randomized-controlled-trial in COVID-19 patients. Randomized patients received either honey (1 gm/Kg/day) and Nigella sativa (80 mg/Kg/day) or placebo upto 13 days. The outcomes included symptoms alleviation, viral clearance, and 30-day mortality.RESULTS Of 313 patients, 210 moderate and 103 severe underwent randomization. Among these 107 were assigned to HNS whereas 103 to placebo for moderate cases. For severe cases, 50 were given HNS and 53 placebo. HNS resulted in symptoms alleviation by 3 and 7 days in moderate and severe disease, respectively (Hazard Ratio [HR]: 6.11; 95% Confidence Interval [CI]: 4.23-8.84, P&lt;0.0001 and HR: 4.04; 95% CI, 2.46-6.64, P&lt;0.0001). HNS also cleared the virus 4 days earlier in moderate (HR: 5.53; 95% CI: 3.76-8.14, P&lt;0.0001) and severe cases (HR: 4.32; 95% CI: 2.62-7.13, P&lt;0.0001). HNS further led to a better clinical score on day 6 with normal activities in 63.6% (moderate, OR: 0.07; 95% CI: 0.03-0.13, P&lt;0.0001) and 28% (severe, OR: 0.03; 95% CI: 0.01-0.09, P&lt;0.0001) patients. A reduction in 30-day mortality among severe patients was shown with HNS (4% versus 18.87%, OR: 0.18; 95% CI: 0.02-0.92, P=0.029). No HNS-related adverse effects were observed.CONCLUSIONS HNS improved symptoms, viral clearance and mortality in COVID-19 patients. Thus, HNS represents an affordable therapy and can be used alone or in combination with other treatments to achieve potentiating effects against COVID-19. (Funded by Smile Welfare Organization, Shaikh Zayed Medical Complex and Services Institute of Medical Sciences; NIH Clinical Trial Register number: NCT04347382.)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04347382Funding StatementFunded by Smile Welfare Organization, Shaikh Zayed Medical Complex and Services Institute of Medical SciencesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan approval ID SZH/IRB/0026/2020 and IRB Services Institute of Medical Sciences, Lahore, Pakistan approval ID IRB/2020/658/SIMSAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical data is available as additional file and raw data can be provided on request to corresponding author